Skip to main content
Full access
Editorials
Published Online: 1 October 2019

On the Specificity of Continuous Cognitive Decline in Schizophrenia

Cognitive dysfunction is a core and defining characteristic of schizophrenia (1). Countless cross-sectional studies, including in large population-based samples, have shown that IQ is lower in patients with schizophrenia, and lower than would be expected on the basis of the educational attainment of their mothers (2) and close relatives (3). The intellectual underperformance precedes the onset of psychosis by a decade (e.g., 4), with more recent longitudinal birth cohort data showing that the decline in IQ is progressive and starts in adolescence (5) if not earlier (6). Surprisingly, despite much more data being available, what happens after illness onset is less clear. Cross-sectional data provide a hint: IQ in schizophrenia patients is two standard deviations lower than that of healthy subjects in samples where IQ is assessed (many years) after illness onset, whereas it is only 0.5 standard deviations lower prior to diagnosis (7). Thus, one would expect IQ to continue to decline after psychosis onset. However, despite this large disparity in IQ deficits before and after psychosis onset, the cross-sectional data have not been confirmed in longitudinal studies (follow-up studies are needed in view of the confounders inherent to cross-sectional designs, such as cohort effects). This is not due to lack of trying: dozens of such studies have been done.
The problem, as Zanelli et al. (8) convincingly argue in an article in this issue, is that the study designs so far have been flawed. The most notable failing is that many of these studies have neglected to include a healthy control group, making it impossible to control for the effects of age and repeated testing (the authors provide an informative table in the online supplement, listing all longitudinal studies that tested cognition in first-episode psychosis patients; only 16 of 39 studies included a healthy control group). Second, follow-up periods were invariably short (usually 5 years or shorter), reducing power when, as expected, the IQ changes per year are small. Finally, the specificity of cognitive change has not been addressed. This issue is as relevant today as it was when “dementia praecox” was contrasted with “manic depressive illness” on the basis of (cognitive) outcome (9). Inconceivable as it sounds, it took more than 125 years after the original description by Kraepelin for the first study to appear that properly examined the cognitive trajectory after psychosis onset (8).
Using a population-based cohort from the United Kingdom, Zanelli et al. (8) tested cognitive function in 106 patients who were being seen for a first psychosis, followed them for an average of 9 years, and compared cognitive trajectories with a similar number of healthy control subjects. Full-scale IQ was estimated on the basis of four WAIS subtests, which has been shown to be a reliable approximation of total IQ. In addition, specific cognitive functions were tested, examining more detailed domains of cognition. The authors’ results show that (normalized) IQ declined in the schizophrenia group (N=65) but not in the patients with other psychoses (N=41), although the effect size was moderate (d=−0.28). In an elegant subanalysis, the authors examined whether, in the healthy comparison subjects with an IQ below 90, cognitive change was larger than in those with an average or higher IQ in order to test whether the excessive IQ decline in the schizophrenia patients could be due to lower cognitive reserve. Interestingly, IQ decline was independent of baseline IQ, suggesting that the excessive IQ decline in schizophrenia is an illness-related phenomenon. The additional finding that IQ decline was larger in the more severely ill patients bolsters this conclusion. For the more specific cognitive tests, patients with schizophrenia showed significant declines in memory functions such as verbal learning and immediate and delayed recall and in verbal knowledge (vocabulary), while the patients with other psychoses showed a decline in verbal learning only. Overall, the decline on the more specific cognitive tests was largest in the schizophrenia group. Medication history (type of antipsychotic, duration of treatment) did not affect the cognitive decline, either in a positive or negative fashion.
In addition to establishing that IQ declines in schizophrenia after psychosis onset, of equal interest is the authors’ finding that the IQ decline was absent in the patients with psychotic disorders other than schizophrenia. Interestingly, the authors underemphasize this result, in fact suggesting the opposite, that is, that the findings do not support the “specificity hypothesis.” However, they base this conclusion on the finding that in some of the specific cognitive tests, both patients with schizophrenia and those with other psychoses showed declines, although the declines were larger across the board in the former. However, the specificity regards a far more important and global measure: IQ. In that respect, the data are both clear and specific: only the schizophrenia patients showed a decline in IQ, thus ruling out the possibility that this is related to psychosis per se. It is unfortunate that the authors to not report how many of the 40-odd “other psychosis” patients were diagnosed with bipolar illness, since then their study could have addressed whether differences in IQ decline were found between the two disorders. If so, their findings would have been consistent with a growing body of evidence that schizophrenia and bipolar illness are more dissimilar than is suggested by the (limited) genetic overlap between them (10). Indeed, the differential IQ decline in schizophrenia after illness onset is in line with a recent report (6) finding that IQ decline in childhood and adolescence is found before illness onset in individuals who go on to develop schizophrenia but not in those who are later diagnosed with affective and other psychoses. The findings are equally consistent with the specificity of brain changes in schizophrenia patients (11) and their offspring (12), as well as abnormalities seen in motor development in individuals who later develop schizophrenia but not in those who go on to develop other psychoses (13). Although genetic overlap is found between schizophrenia, bipolar illness, and intelligence, the direction of this relationship in schizophrenia is the mirror image from that in bipolar illness; in schizophrenia risk genes are related to lower intelligence, and in bipolar illness to higher IQ (14).
What does the general cognitive decline after illness onset signify? First, it should be noted that although the patients were seen during their first psychosis, the average age at study inclusion was almost 30 years, which is quite high for a first psychosis. Rather than these patients being in the early stages of their illness, their psychotic symptoms may have been ongoing for quite a few years. Moreover, cognitive decline precedes the onset of the first psychosis by more than a decade (46), suggesting that the IQ decline in the Zanelli et al. study may be a continuation of a process that has been under way for decades. However, this does not preclude an additional process taking place after the onset of psychosis. Indeed, the excessive decline in IQ in schizophrenia has been related to progressive loss of cortical gray matter volume after illness onset (15). This loss could be related to a general accelerated aging of the brain (16), although the specificity in some of the cognitive domains reported by Zanelli et al., such as verbal knowledge and memory, argues against this.
Although the cognitive decline was related to severity of symptoms at baseline, but not to change in severity over time, the report does not specify whether it was related to number of hospitalizations and psychotic relapses; it would be important if these data could still be made available. Finally, the authors’ finding that of the more specific cognitive domains, verbal functions and memory were particularly affected in schizophrenia is consistent with the large body of literature reporting hippocampal involvement in schizophrenia (17) but not in bipolar illness (18).
Despite a relatively small sample, the Zanelli et al. study is the first to convincingly suggest that the cognitive decline that begins years or even decades before the onset of the first psychosis continues for many years afterward, is specific to schizophrenia, and is relatively unaffected by antipsychotic medication. These findings should serve as a clarion call to study the causes of this cognitive decline, since once we understand the cognitive decline in schizophrenia, we will understand schizophrenia itself.

Footnote

The author has served as a consultant for Alkermes, Luye Pharma, Otsuka, and Sunovion. Dr. Kalin has reviewed this editorial and found no evidence of influence from these relationships.

References

1.
Kahn RS, Keefe RS: Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry 2013; 70:1107–1112
2.
Keefe RS, Eesley CE, Poe MP: Defining a cognitive function decrement in schizophrenia. Biol Psychiatry 2005; 57:688–691
3.
Kendler KS, Ohlsson H, Mezuk B, et al: Observed cognitive performance and deviation from familial cognitive aptitude at age 16 years and ages 18 to 20 years and risk for schizophrenia and bipolar illness in a Swedish national sample. JAMA Psychiatry 2016; 73:465–471
4.
van Oel CJ, Sitskoorn MM, Cremer MP, et al: School performance as a premorbid marker for schizophrenia: a twin study. Schizophr Bull 2002; 28:401–414
5.
Reichenberg A, Caspi A, Harrington H, et al: Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am J Psychiatry 2010; 167:160–169
6.
Mollon J, David AS, Zammit S, et al: Course of cognitive development from infancy to early adulthood in the psychosis spectrum. JAMA Psychiatry 2018; 75:270–279
7.
Woodberry KA, Giuliano AJ, Seidman LJ: Premorbid IQ in schizophrenia: a meta-analytic review. Am J Psychiatry 2008; 165:579–587
8.
Zanelli J, Mollon J, Sandin S, et al: Cognitive change in schizophrenia and other psychoses in the decade following the first episode. Am J Psychiatry 2019; 176:811–819
9.
Kraepelin E: Psychiatre: ein Lehrbuch für Studierende und Ärzte, 4th ed. Leipzig, Germany, Verlag von Johann Ambrosius Barth, 1893, pp 435–444
10.
Cross-Disorder Group of the Psychiatric Genomics Consortium: Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013; 381:1371–1379
11.
Schnack HG, Nieuwenhuis M, van Haren NE, et al: Can structural MRI aid in clinical classification? A machine learning study in two independent samples of patients with schizophrenia, bipolar disorder, and healthy subjects. Neuroimage 2014; 84:299–306
12.
de Zwarte SMC, Brouwer RM, Agartz I, et al: The association between familial risk and brain abnormalities is diseasespecific: an ENIGMA–Relatives study of schizophrenia and bipolar disorder. Biol Psychiatry (in press)
13.
Burton BK, Thorup AAE, Jepsen JR, et al: Impairments of motor function among children with a familial risk of schizophrenia or bipolar disorder at 7 years old in Denmark: an observational cohort study. Lancet Psychiatry 2017; 4:400–408
14.
Smeland OB, Bahrami S, Frei O, et al: Genome-wide analysis reveals extensive genetic overlap between schizophrenia, bipolar disorder, and intelligence. Mol Psychiatry (Epub ahead of print, January 4, 2019)
15.
Kubota M, van Haren NE, Haijma SV, et al: Association of IQ changes and progressive brain changes in patients with schizophrenia. JAMA Psychiatry 2015; 72:803–812
16.
Schnack HG, van Haren NE, Nieuwenhuis M, et al: Accelerated brain aging in schizophrenia: a longitudinal pattern recognition study. Am J Psychiatry 2016; 173:607–616
17.
Tamminga CA, Stan AD, Wagner AD: The hippocampal formation in schizophrenia. Am J Psychiatry 2010; 167:1178–1193
18.
Arnold SJ, Ivleva EI, Gopal TA, et al: Hippocampal volume is reduced in schizophrenia and schizoaffective disorder but not in psychotic bipolar I disorder demonstrated by both manual tracing and automated parcellation (FreeSurfer). Schizophr Bull 2015; 41:233–249

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 774 - 776
PubMed: 31569987

History

Accepted: 2 August 2019
Published online: 1 October 2019
Published in print: October 01, 2019

Keywords

  1. Schizophrenia
  2. Psychosis
  3. Cognitive Neuroscience

Authors

Details

René S. Kahn, M.D., Ph.D. [email protected]
Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai, New York; and James J. Peters Veterans Affairs Medical Center, Bronx, N.Y.

Notes

Send correspondence to Dr. Kahn ([email protected]).

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share